Suppr超能文献

在脓毒症诊断时开始的血液净化治疗可有效减轻血清高迁移率族蛋白B1(HMGB1)的上调,并改善患者预后。

Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

作者信息

Zheng Shixiang, Weng Qinyong, Wu Wenwei, Ding Guohua

机构信息

Division of Critical Care Medicine, Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China.

Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430000, P.R. China.

出版信息

Exp Ther Med. 2017 Oct;14(4):3029-3035. doi: 10.3892/etm.2017.4854. Epub 2017 Jul 31.

Abstract

The aim of the present study was to investigate the increase in serum and urine levels of high mobility group box protein 1 (HMGB1) during sepsis and the effect of blood purification treatments on HMGB1 levels and patient prognosis. A total of 40 intensive care patients with sepsis were randomly assigned to different groups (n=10 per group): A control group (sepsis group), a continuous renal replacement treatment (CRRT) group, a hemoperfusion (HP) group and an HP+CRRT group. The blood purification treatments using HP and/or CRRT were performed immediately after the diagnosis of sepsis. HMGB1 levels were measured using ELISA, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores and 30-day survival rates were evaluated. Relative to a healthy control group (n=10), HMGB1 levels were observed to be significantly upregulated during sepsis (P<0.05). Following the initiation of sepsis, serum HMGB1 continued to increase in the sepsis group and was significantly elevated at 24 h (P<0.05), whereas urine HMGB1 levels decreased significantly at 12 and 24 h (P<0.05). Serum HMGB1 levels were significantly positively correlated with APACHE II scores (r=0.7284, P<0.01) and significantly negatively correlated with urine HMGB1 levels (r=-0.5103, P=0.026). Serum HMGB1 levels were significantly reduced in the HP and HP+CRRT groups by 12 and 24 h following the initiation of treatment (both P<0.05). Changes in the urine HMGB1 level differed in each group. Relative to the sepsis group, the APACHE II scores of all blood purification groups were significantly reduced (P<0.05) and the 30-day survival rate of the HP+CRRT group was significantly increased (P=0.0107). The results of the present study indicate that blood purification initiated at the point of diagnosis in patients with sepsis may attenuate serum HMGB1 upregulation, promote urinary excretion of HMGB1 and improve the prognosis of sepsis.

摘要

本研究旨在探讨脓毒症期间血清和尿液中高迁移率族蛋白B1(HMGB1)水平的升高情况,以及血液净化治疗对HMGB1水平和患者预后的影响。总共40例脓毒症重症监护患者被随机分为不同组(每组n = 10):一个对照组(脓毒症组)、一个持续肾脏替代治疗(CRRT)组、一个血液灌流(HP)组和一个HP + CRRT组。在诊断脓毒症后立即进行使用HP和/或CRRT的血液净化治疗。使用酶联免疫吸附测定法(ELISA)测量HMGB1水平,并评估急性生理与慢性健康状况评分系统(APACHE)II评分和30天生存率。相对于健康对照组(n = 10),观察到脓毒症期间HMGB1水平显著上调(P < 0.05)。脓毒症发作后,脓毒症组血清HMGB1持续升高,并在24小时时显著升高(P < 0.05),而尿液HMGB1水平在12小时和24小时时显著降低(P < 0.05)。血清HMGB1水平与APACHE II评分显著正相关(r = 0.7284,P < 0.01),与尿液HMGB1水平显著负相关(r = -0.5103,P = 0.026)。治疗开始后12小时和24小时,HP组和HP + CRRT组血清HMGB1水平显著降低(均P < 0.05)。每组尿液HMGB1水平的变化有所不同。相对于脓毒症组,所有血液净化组的APACHE II评分均显著降低(P < 0.05),HP + CRRT组的30天生存率显著提高(P = 0.0107)。本研究结果表明,脓毒症患者在诊断时开始进行血液净化可能会减弱血清HMGB1的上调,促进HMGB1的尿液排泄,并改善脓毒症的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5297/5585716/867678fff4dc/etm-14-04-3029-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验